The FDA has greenlit Travere Therapeutics’ Filspari as the only available treatment for focal segmental glomerulosclerosis despite the drug’s loss to Sanofi’s Avapro in a Phase 3 study.
Phase 2 randomized trial shows 38% reduction in risk of death with the drug when combined with chemotherapy
Protaryx Medical announced that it received FDA 510(k) clearance for its proprietary Transseptal Puncture Device.
A research team has developed a “self-regulating OLED wound healing patch” that combines light and drugs to pull up the wound recovery speed by about twice.
A major multi-site clinical trial co-led by researchers at Washington University School of Medicine in St. Louis has shown that post-thrombotic syndrome—a common and often painful complication suffered by many people who have experienced blockages of major veins due to blood clots—can be effectively treated with a minimally invasive procedure.
A Korean research team has developed a low-frequency-based wireless sensor technology.
ProSomnus announced today that it received FDA 510(k) clearance for its RPMO₂ obstructive sleep apnea (OSA) therapy device.
Used with Beckman’s immunoassay analysers, MeMed’s BV test has been demonstrated to reduce unnecessary antibiotic use.
Learn how an isolated but collaborative bird species shows that close social contact can shape our gut microbes in surprising ways.
By using AI to analyze more than 400,000 Reddit posts, Penn researchers have identified patient-reported symptoms associated with GLP-1s, the popular weight-loss and diabetes drugs semaglutide and tirzepatide, that may not be fully captured in clinical trials or regulatory documents.